COMPASS Pathways' COMP360 shows durable efficacy in two Phase 3 trials for treatment-resistant depression, with FDA submission on track for Q4 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results